PHARMACEUTICAL COMBINATION AND USE THEREOF
A pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a PD-1 inhibitor and/or a PD-L1 immune checkpoint inhibitor; and a STING pathway agonist. The pharmaceutical combination has a better antitumor efficacy than an immune checkpoint inhibitor alone or a STING pathway agonist alone, realizes treatment by both innate immune pathway activation of organisms and immune escape prevention, and thus has efficient and low-toxicity clinical application prospects..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Europäisches Patentamt - (2022) vom: 24. Nov. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
WANG CHENGUANG [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2022-11-24, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 |
|---|
| Patentnummer: |
WO2022242737 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018866573 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018866573 | ||
| 003 | DE-627 | ||
| 005 | 20240209083302.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231229s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018866573 | ||
| 035 | |a (EPA)WO2022242737 | ||
| 035 | |a (EPA)84140260 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a WANG CHENGUANG |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHARMACEUTICAL COMBINATION AND USE THEREOF |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2022-11-24, Last update posted on www.tib.eu: 2024-02-06, Last updated: 2024-02-09 | ||
| 520 | |a A pharmaceutical combination and a use thereof. The pharmaceutical combination comprises a PD-1 inhibitor and/or a PD-L1 immune checkpoint inhibitor; and a STING pathway agonist. The pharmaceutical combination has a better antitumor efficacy than an immune checkpoint inhibitor alone or a STING pathway agonist alone, realizes treatment by both innate immune pathway activation of organisms and immune escape prevention, and thus has efficient and low-toxicity clinical application prospects. | ||
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a ZHANG XIAOJIAO |4 aut | |
| 700 | 0 | |a DANG XIAOMENG |4 aut | |
| 700 | 0 | |a ZHANG JIN |4 aut | |
| 700 | 0 | |a FU YUTING |4 aut | |
| 700 | 0 | |a WANG YIHAN |4 aut | |
| 700 | 0 | |a WANG CHAO |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2022) vom: 24. Nov. |
| 773 | 1 | 8 | |g year:2022 |g day:24 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/84140260/publication/WO2022242737A1?q=WO2022242737 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2022 |b 24 |c 11 |
| 951 | |a AR | ||
| 952 | |j 2022 |b 24 |c 11 | ||